Ajay Sunny, Correspondent at India Pharma Outlook
Pharmaceutical manufacturing workers form the backbone of resilient domestic and global drug supply chains. They operate in highly regulated, sterile environments to produce, package, and ensure the quality of essential medicines, from everyday generics to complex biologics and potent therapies. In an era of geopolitical tensions, pandemics, and raw material vulnerabilities, these frontline professionals maintain production continuity, prevent shortages, and safeguard patient access to life-saving drugs. Their expertise in adhering to Good Manufacturing Practices (GMP), quality controls, and safety protocol Guide directly supports supply chain integrity, enabling timely delivery across borders while minimizing disruptions from quality issues or contamination events. Without a skilled, healthy workforce, even advanced facilities risk downtime, recalls, or failures that ripple through healthcare systems worldwide.
Despite the critical nature of their role, pharmaceutical workers face significant occupational hazards. Repetitive tasks such as capping, labeling, pipetting, manual material handling, and packaging—often performed in cleanrooms under time pressure—contribute to high rates of musculoskeletal disorders (MSDs). Studies on pharmaceutical workers report MSD prevalence ranging from approximately 63% to over 83%, with common complaints in the lower back, neck, shoulders, wrists/hands, and lower extremities. Symptoms include aches, pain, cramps, and moderate severity that still allows work but leads to discomfort, reduced productivity, and potential long-term disability.
Broader manufacturing data underscores the scale: In the U.S. private sector, MSDs accounted for about 30% of days-away-from-work (DAFW) cases in recent years, with manufacturing among the top contributors alongside retail and healthcare. Median DAFW for MSD cases hovers around 12 days, imposing substantial costs through lost productivity, medical expenses, and workers’ compensation. Factors exacerbating risks include prolonged standing, awkward postures, high repetition, and extended shifts (e.g., over 8 hours), which elevate ergonomic strain in pharma’s high-volume lines.
Chemical exposure presents another major threat. Workers handle Active Pharmaceutical Ingredients (APIs), many of which are potent compounds capable of causing adverse effects at very low concentrations via inhalation, skin contact, or accidental ingestion. Risks include respiratory irritation, dermatitis, systemic toxicity, and long-term effects from potent or highly potent substances. While full-shift exposures often stay below limits with proper controls, short-term peaks during tasks like powder scooping or equipment cleaning can spike dust or vapor levels. Industry-wide, chemical-related injuries, though declining as a percentage of total cases, still result in thousands of incidents annually, with potential for acute poisonings or chronic conditions. Dermatitis from repeated PPE use or cleaning agents is also common.
These issues threaten not only worker health but also supply chain stability: injured or ill workers lead to absenteeism, training burdens, reduced output, and higher error rates that could compromise product quality.
Also Read: India Pharma Startups: Navigating Growth Funding and Market Reality
Pharmaceutical manufacturing is, at its core, a hands-on industry. Despite increasing automation in upstream synthesis, the downstream operations — blister packing, manual capping, label application, tablet counting, ampoule inspection, and secondary packaging — remain heavily reliant on human dexterity performed at pace, under pressure, and at scale. A packaging operator on a 12-hour shift may perform the same wrist flexion-extension movement upwards of 8,000–12,000 times. This is the epidemiological breeding ground for Repetitive Strain Injuries (RSI), carpal tunnel syndrome, rotator cuff tendinopathy, and lower back dysfunction — collectively categorised as Musculoskeletal Disorders (MSDs).
Workstation adjustment is equally non-negotiable. The principle of neutral posture — maintaining the spine in its natural lordotic and kyphotic curves, keeping elbows at approximately 90 degrees during manual tasks, and ensuring that the work surface height is positioned to eliminate shoulder elevation — is the foundation of MSD prevention. In cleanroom environments, this is complicated by the need for gowning, restricted footwear, and the absence of conventional ergonomic furniture. The following checklist addresses this challenge directly.
Active Pharmaceutical Ingredients (APIs) are, by molecular design, biologically active at microgram quantities. This pharmacological potency — the very property that makes them therapeutic — also makes occupational exposure a critical risk. Workers in API synthesis, granulation, blending, and sterile filling operations may be exposed to potent compounds that carry Occupational Exposure Limits (OELs) measured in nanograms per cubic metre of air. A single shift's inadequate containment can result in acute toxicity, hormonal disruption, reproductive harm, or long-term carcinogenesis.
The industry standard framework for managing this risk is the Hierarchy of Controls — a structured, prioritised approach to hazard management that moves from the most effective permanent solutions to the least effective temporary measures. Dr. Venkataraman emphasises that in high-potency API environments, the hierarchy is not a philosophical guide but a legal and engineering mandate.
HEPA filtration — High-Efficiency Particulate Air filtration — is the cornerstone of engineering control for potent compounds. Facility design must ensure that OEB 4/5 handling areas operate under negative pressure relative to adjacent spaces, with HEPA-filtered exhaust. HVAC systems must be validated for HEPA filter integrity (using DOP/PAO challenge testing) on a minimum bi-annual basis, or following any facility modification. Potent compound containment failures must trigger immediate area evacuation, biological monitoring of exposed workers, and root cause investigation under a documented CAPA (Corrective and Preventive Action) framework.
Cleanrooms impose unique burdens: full-body gowns, hoods, booties, gloves, and often respirators or powered air systems restrict movement, vision, and heat dissipation. Workers perform precise tasks under these constraints, increasing risks of heat stress, fatigue, restricted visibility (fogging, limited peripheral view), and dermatitis from prolonged occlusion or cleaning residues.
Actionable Steps:
Regular health surveillance and feedback loops help tailor PPE to tasks.
Also Read: World Health Day: How Global Healthcare is Evolving in 2026
The convergence of Industry 4.0 and pharmaceutical GMP is rapidly reshaping the occupational safety landscape of drug manufacturing. The most transformative development is the deployment of Collaborative Robots — universally known as Cobots — in high-risk manual operations. Unlike conventional industrial robots that require physical separation from human workers, cobots are designed with force-limiting sensors, soft-stop functions, and spatial awareness that allow them to operate safely within shared human workspaces without guarding barriers.
In the pharmaceutical context, cobots are being deployed to absorb the highest-risk categories of manual work: heavy tray loading and unloading in autoclave operations (eliminating MSDs from repetitive heavy lifting), continuous blister-pack feeding and carton erecting (eliminating RSI from repetitive motion tasks), and vial inspection operations requiring sustained visual concentration under bright lighting (reducing eye strain and associated error rates). The risk reduction case for cobots is not aspirational — it is increasingly evidenced.
Beyond cobots, AI-powered environmental monitoring systems are beginning to replace periodic manual air sampling in high-potency areas, providing continuous real-time OEL breach alerts and predictive maintenance signals for containment equipment. Digital wearables — including smart bands that monitor heart rate variability, skin temperature, and movement patterns — are being piloted by forward-looking EHS teams at Indian pharma majors to provide early-warning signals for heat stress and ergonomic over-exertion, enabling supervisory intervention before injury occurs.
The ethical dimension of automation in pharma safety deserves direct address: cobot deployment and AI monitoring are not instruments of workforce reduction. They are, when implemented within a worker-centric safety culture, instruments of workforce protection. The workers displaced from the most hazardous repetitive tasks must be upskilled into cobot operation, maintenance, and quality oversight roles — a transition that India's National Skill Development Corporation (NSDC) and the Pharma Sector Skill Council are actively facilitating through certified training programmes.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")